Credit Suisse commits $250 million to Israeli healthcare fund
Reuters
Published May 16, 2018 06:02
Credit Suisse commits $250 million to Israeli healthcare fund
TEL AVIV (Reuters) - Israel-based healthcare fund aMoon II has secured a $250 million (185 million pounds) investment commitment from Credit Suisse (S:CSGN), the fund’s managing partner Yair Schindel said on Wednesday.
Last month the fund, which is investing in mid- to late-stage companies with a focus on fields like digital health, medical technology and biopharma in Israel, the United States and Europe, said it had raised $200 million from private investors.
The Credit Suisse financing from its asset management and private banking divisions brings the fund close to meeting its target of $500 million. The remainder of the funding is expected to be raised within a few months from other financial institutions and wealthy individuals.
The fund intends to invest $10 million to $40 million in 15 to 20 companies.
aMoon is a life sciences investment fund founded in 2016 by Marius Nacht, co-founder and chairman of Check Point Software Technologies (O:CHKP), and Schindel.
Nacht and Schindel's previous fund, aMoon I, focused on the early stage, investing in 16 startups.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.